6 completed, 4 recruiting, 2 not yet recruiting. 4 Not applicable, 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 4 | Completed 2, Recruiting 2 |
| Phase 2 | 4 | Not yet recruiting 2, Completed 1, Recruiting 1 |
| Phase 1 | 3 | Completed 2, Recruiting 1 |
Follow Overweight or Obese: new trials by email Literature Review of Overweight or Obese trials Research Report on Overweight or Obese
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Weight Loss Via Intelligent Guidance in Patients With Coronary Heart Disease and Obesity: a Randomized Clinical Trial dietary regulation and structured exercise training - CHD, Overweight or Obese | Not applicable | Recruiting | Guangdong Provincial People's Hospital | 140 | 2026-04-18 | 2026-05-12 |
| Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB) Tirzepatide, Take Control CBT Module, Placebo - Alcohol Use Disorder (AUD), Overweight or Obese | Phase 2 | Not yet recruiting | South West Sydney Local Health District | 46 | 2026-01-15 | 2025-12-18 |
| Innovative Functional Product for Overweight and Obesity Polyphenol-enriched functional product, Control without active polyphenols - Obesity and Overweight, Overweight or Obese | Not applicable | Completed | Carmen Lucas Abellán | 70 | 2025-09-07 | 2026-02-17 |
| Pistachio Snacking and Metabolic Flexibility Pistachio - Overweight (BMI > 25), Obese But Otherwise Healthy Participants | Not applicable | Recruiting | University of South Carolina | 60 | 2025-09-01 | 2026-01-14 |
| A Trial With EMP16 in Preparation for Late Phase Studies EMP16-02 120 mg orlistat/40 mg acarbose, Alli® 60 mg, Vi-Siblin® S - Overweight or Obese, Obesity and Overweight | Phase 2 | Not yet recruiting | Empros Pharma AB | 39 | 2025-05-20 | 2025-05-28 |
| A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal Function BGM0504 - Type 2 Diabetes Mellitus (T2DM), Overweight or Obese | Phase 1 | Completed | BrightGene Bio-Medical Technology Co., Ltd. | 34 | 2025-05-06 | 2026-10-13 |
| A Study of BGM0504 in Overweight or Obese Participants Paracetamol, Metformin Hydrochloride, Warfarin - Overweight or Obese | Phase 1 | Completed | BrightGene Bio-Medical Technology Co., Ltd. | 28 | 2025-03-25 | 2026-10-13 |
| A Study to Evaluate MWN109 Injection in Healthy Subjects Placebo, Subcutaneous single and mutiple dose - Overweight or Obese | Phase 1 | Recruiting | Shanghai Minwei Biotechnology Co., Ltd | 72 | 2025-03-17 | 2025-04-15 |
| Phase II Study of THDBH120 Injection in Overweight or Obese Subjects THDBH120 injection, Placebo of THDBH120 injection - Overweight or Obese | Phase 2 | Recruiting | Tonghua Dongbao Pharmaceutical Co.,Ltd | 276 | 2025-01-06 | 2025-06-25 |
| A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus Placebo, Enicepatide - Overweight or Obese, Type 2 Diabetes Mellitus (T2DM) | Phase 2 | Completed | Carmot Therapeutics, Inc. | 447 | 2024-11-21 | 2026-10-28 |
| Weight Management in Mothers and Adult Daughters Communication, Standard - Overweight or Obese | Not applicable | Completed | University of California, San Diego | 54 | 2018-08-01 | 2021-10-12 |
| Dose-Response to Exercise in Women Aged 45-75 Years (DREW) Exercise - Cardiovascular Diseases, Hypertension | Completed | Pennington Biomedical Research Center | 464 | 2001-01-01 | 2022-09-15 |
Obesity (12) · Overweight (12) · Diabetes Mellitus, Type 2 (2) · Alcoholism (1) · Cardiovascular Diseases (1) · Hypertension (1) · Sedentary Behavior (1)
Body Weight (12) · Nutrition Disorders (12) · Nutritional and Metabolic Diseases (12) · Overnutrition (12) · Pathological Conditions, Signs and Symptoms (12) · Signs and Symptoms (12) · Diabetes Mellitus (2) · Endocrine System Diseases (2) · Glucose Metabolism Disorders (2) · Metabolic Diseases (2) · Alcohol-Related Disorders (1) · Behavior (1) · Chemically-Induced Disorders (1) · Mental Disorders (1) · Substance-Related Disorders (1)
Acetaminophen (1) · Exercise (1) · Metformin (1) · Orlistat (1) · Tirzepatide (1) · Warfarin (1) · maltodextrin (1)
BrightGene Bio-Medical Technology Co., Ltd. (2) · Carmen Lucas Abellán (1) · Carmot Therapeutics, Inc. (1) · Empros Pharma AB (1) · Guangdong Provincial People's Hospital (1) · Pennington Biomedical Research Center (1) · Shanghai Minwei Biotechnology Co., Ltd (1) · South West Sydney Local Health District (1) · Tonghua Dongbao Pharmaceutical Co.,Ltd (1) · University of California, San Diego (1) · University of South Carolina (1)
China (4) · United States (4) · Australia (2) · Argentina (1) · Canada (1) · Mexico (1) · New Zealand (1) · Puerto Rico (1) · Spain (1)
Conrad P. Earnest, PhD (1) · Guitao Zhang (1) · Helena Litorp, MD, PhD (1) · James S. Skinner, hD (1) · Katie R Hirsch, PhD (1) · Paul Haber, MD, RACP, FAChAM (1) · Steven N. Blair, PED (1) · Timothy S. Church, MD, PhD, MPH (1)
PMID 17507344, PMID 18523583, PMID 19204218, PMID 19223984, PMID 19952829, PMID 22363616, PMID 22798253
R01HL066262 (1)